Alnylam Pharmaceuticals

IPO

SILENCE DISEASE. AMPLIFY LIFE.

Public · Cambridge, United States · Founded 2002 · $1.0B raised

Employees
1001–5000
Founded
2002
Business Model
B2B
Total Funding
$1.0B
Last Round
$1.0B Corporate RoundApr 2020
Rounds
3
Type
Public

Totals include recorded grants and other qualifying funding, not just equity. What counts toward funding.

About

Alnylam Pharmaceuticals is the pioneer and global leader in RNA interference (RNAi) therapeutics, having discovered the mechanism and translated it into six FDA-approved medicines since 2018. The company develops small interfering RNA (siRNA) drugs that silence disease-causing genes at their source, targeting rare diseases, cardiovascular disease, and neurological conditions. Headquartered in Cambridge, Massachusetts, Alnylam employs 2,500+ people and operates globally across six continents.

Summary

Alnylam Pharmaceuticals is a Biotech company based in Cambridge, United States, founded in 2002. It has raised $1.0B in total across 3 rounds, most recently a $1.0B Corporate Round in Apr 2020. Investors include Blackstone.

Tech & App Stack

7 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding & Exit History

Corporate RoundCorporate RoundApr 2020
$1.0B

Sign up to see all 4 events

Funding: Seed through Corporate Round. Amounts, valuations, and investors where available.

Investors

Similar Companies

GRAILIPO

Biotechnology company developing multi-cancer early detection blood tests using high-intensity ge...

Menlo Park, United States1001–5000Biotech, Genomics
Corporate RoundTotal funding$2.1BJun 2026
Paratek PharmaceuticalsAcquired

Paratek Pharmaceuticals develops and delivers innovative treatments for serious infectious diseas...

Boston, United States201–500Biotech, Healthcare
ConvertibleTotal funding$1.8BApr 2018
Sana BiotechnologyIPO

Developer of engineered cells as medicines to treat diseases by repairing or replacing cells for ...

Seattle, United States201–500Biotech, Healthcare
Series DTotal funding$1.4BJun 2020
Abogen Biosciences

Abogen Biosciences develops RNA therapeutics using integrated mRNA design, lipid nanoparticle del...

Suzhou, China201–500Biotech, Drug Discovery
Extension RoundTotal funding$1.2BNov 2021
Ultima Genomics

Ultima Genomics develops high-throughput DNA sequencing platforms that use open-wafer technology ...

Fremont, United States201–500Artificial Intelligence, Healthcare
Series ETotal funding$1.1BJun 2022
ArsenalBio

Clinical-stage programmable cell therapy company developing engineered T-cell therapies for solid...

San Francisco, United States201–500Biotech, Life Sciences
Series CTotal funding$955.0MSep 2024

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

Alnylam Pharmaceuticals on Indexed.vc
<a href="https://indexed.vc/companies/alnylam-pharmaceuticals"><img src="https://indexed.vc/api/badge/company/alnylam-pharmaceuticals" alt="Alnylam Pharmaceuticals on Indexed.vc" width="260" height="76" /></a>